Background
A big pharma company wanted to foster change in payer attitudes to increase the acceptance of patient-reported outcomes (PROs) and of endpoints beyond overall survival in reimbursement decision-making for oncology drugs.
L.E.K.’s approach
L.E.K. Consulting conducted extensive secondary and primary research, including a market research focus group, to articulate the value story for non-overall survival endpoints and PROs. We also sought to understand the key concerns preventing greater use of these endpoints/PROs in health technology assessments (HTAs).
We then tailored the content for external dissemination (e.g., ESMO 2022 oral presentation, ISPOR Europe 2022 poster presentation) and created a playbook of dissemination materials for other external events. We also developed a series of articles for peer-reviewed journals.
Value delivered to the client
We provided materials to the client to support its ongoing internal and external engagement strategy as well as a cross-stakeholder action plan to execute (see Figure 1).
